KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Fulgent Genetics (FLGT) Revenue (2016 - 2026)

Fulgent Genetics' Revenue history spans 12 years, with the latest figure at $71.1 million for Q1 2026.

  • On a quarterly basis, Revenue fell 3.16% to $71.1 million in Q1 2026 year-over-year; TTM through Mar 2026 was $237.4 million, a 18.82% decrease, with the full-year FY2025 number at $322.7 million, up 13.83% from a year prior.
  • Revenue hit $71.1 million in Q1 2026 for Fulgent Genetics, up from $400000.0 in the prior quarter.
  • Over the last five years, Revenue for FLGT hit a ceiling of $320.3 million in Q1 2022 and a floor of $400000.0 in Q4 2025.
  • Historically, Revenue has averaged $89.7 million across 5 years, with a median of $72.6 million in 2024.
  • The widest YoY moves for Revenue: up 17.18% in 2025, down 99.48% in 2025.
  • Tracing FLGT's Revenue over 5 years: stood at $105.7 million in 2022, then tumbled by 33.27% to $70.5 million in 2023, then rose by 8.1% to $76.2 million in 2024, then crashed by 99.48% to $400000.0 in 2025, then skyrocketed by 17684.5% to $71.1 million in 2026.
  • Business Quant data shows Revenue for FLGT at $71.1 million in Q1 2026, $400000.0 in Q4 2025, and $84.1 million in Q3 2025.